---
layout: default
title: Arnica Montana Whole Arsenic Trioxide Avena Sativa
parent: 僅模型預測 (L5)
nav_order: 411
evidence_level: L5
indication_count: 0
---

# Arnica Montana Whole Arsenic Trioxide Avena Sativa
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Complex (31 Ingredients): Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This product is a 31-ingredient complex containing homeopathic botanical extracts, mineral compounds, animal organ preparations, and Arsenic Trioxide, with no registered indication in Taiwan and no DrugBank identifier on file.
The TxGNN model returned **no predicted indications** for this candidate, likely because the multi-ingredient composition could not be resolved to a single mappable entity.
Currently, **0 clinical trials** and **0 publications** are linked to this compound through the automated pipeline.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (no regulatory record) |
| Predicted New Indication | None (TxGNN returned no prediction) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction only; in this case no prediction was generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction was generated for this candidate. The pipeline likely failed to map the compound because the query string consists of 31 distinct ingredients rather than a single INN, and no DrugBank ID is available to anchor the knowledge-graph traversal.

The composition spans four pharmacological classes: (1) homeopathic botanical extracts (Arnica Montana, Avena Sativa, Ruta Graveolens, Nuphar Lutea, Veratrum Album, Smilax Ornata, Lycopodium Clavatum, Chaste Tree Fruit, Saw Palmetto); (2) inorganic mineral salts (Calcium Fluoride, Calcium Sulfate, Barium Carbonate, Potassium Chloride, Sodium Sulfate, Manganese Sulfate, Zinc Chloride, and phosphate salts); (3) porcine organ preparations (adrenal gland, hypothalamus, pancreas, pituitary gland, testicle); and (4) a cytotoxic heavy metal (Arsenic Trioxide). This heterogeneity makes unified mechanism-of-action analysis impossible without first resolving the formulation's regulatory classification and intended indication.

Until the product is registered under a single INN or a parent drug is designated, meaningful repurposing analysis cannot proceed.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

No US (NDA) or Taiwan regulatory authorizations on file for this product.

---

## Cytotoxicity

> **Note:** One component of this formulation — **Arsenic Trioxide** — is a classified antineoplastic agent (FDA-approved for acute promyelocytic leukemia, NDA 021248). In the context of homeopathic preparations, arsenic trioxide is typically used at extreme dilutions (≥ 12C), where measurable pharmacological activity is not established. The table below reflects the properties of pharmaceutical-grade arsenic trioxide; applicability to this formulation is unknown pending clarification of the arsenic content and dilution factor.

| Item | Content |
|------|---------|
| Cytotoxicity Classification | Conventional cytotoxic (inorganic arsenical) — applicable only if arsenic trioxide concentration is pharmacologically relevant |
| Myelosuppression Risk | High for pharmaceutical-grade arsenic trioxide (leukocytosis, QTc prolongation, differentiation syndrome) |
| Emetogenicity Classification | Low to moderate |
| Monitoring Items | CBC with differential, serum electrolytes (K⁺, Mg²⁺), 12-lead ECG (QTc), liver function tests |
| Handling Protection | If arsenic trioxide is present at pharmacological concentrations, cytotoxic drug handling regulations apply; confirm formulation concentration before handling classification |

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Additional note:** The presence of **Arsenic Trioxide** in this formulation warrants special attention regardless of dilution. Arsenic trioxide at pharmaceutical doses carries Black Box Warnings for APL differentiation syndrome and QTc prolongation. The porcine organ preparations (Sus Scrofa hypothalamus, pituitary, pancreas, adrenal, testicle) raise theoretical concerns for prion transmission; regulatory guidance on animal-derived biologics should be consulted.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The automated pipeline could not generate any TxGNN prediction for this candidate because the 31-ingredient composition cannot be mapped to a single DrugBank node or knowledge-graph entity. There is no Taiwan regulatory record, no original indication, and no evidence foundation to evaluate repurposing potential.

**To proceed, the following is needed:**

- **Formulation clarification**: Determine whether this is a registered homeopathic product, a nutraceutical, or a compounded pharmaceutical, and obtain the official product monograph or package insert.
- **Arsenic Trioxide concentration verification**: Confirm the dilution factor of the arsenic trioxide component to establish whether pharmaceutical-grade toxicity guidance applies.
- **Single-entity decomposition**: If repurposing analysis is desired for individual ingredients (e.g., Arsenic Trioxide for hematologic malignancies, Saw Palmetto for BPH), each ingredient should be submitted as a separate Evidence Pack query with its own INN and DrugBank ID.
- **MOA documentation**: Obtain mechanism-of-action data from DrugBank for any pharmacologically active components before re-running the TxGNN pipeline.
- **Regulatory status review**: Clarify the product's legal classification under Taiwan TFDA and US FDA frameworks (homeopathic OTC, dietary supplement, or prescription drug) to determine the applicable regulatory pathway.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

